Cybin (HELP) Competitors

$4.67 -0.39 (-7.71%)

Closing price 04:00 PM Eastern

Extended Trading

$4.70 +0.03 (+0.54%)

As of 07:59 PM Eastern

HELP vs. SVRA, CVAC, CRON, AKTS, and DSGN

Should you buy Cybin stock or one of its competitors? MarketBeat compares Cybin with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cybin include Savara (SVRA), CureVac (CVAC), Cronos Group (CRON), Aktis Oncology (AKTS), and Design Therapeutics (DSGN). These companies are all part of the "pharmaceutical products" industry.

How does Cybin compare to Savara?

Cybin (NASDAQ:HELP) and Savara (NASDAQ:SVRA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

17.9% of Cybin shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cybin currently has a consensus price target of $58.75, indicating a potential upside of 1,158.03%. Savara has a consensus price target of $9.13, indicating a potential upside of 81.41%. Given Cybin's stronger consensus rating and higher possible upside, equities analysts plainly believe Cybin is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Savara	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Cybin's return on equity of -59.98% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-59.98%	-50.80%
Savara	N/A	-87.19%	-66.42%

In the previous week, Savara had 11 more articles in the media than Cybin. MarketBeat recorded 12 mentions for Savara and 1 mentions for Cybin. Cybin's average media sentiment score of 1.71 beat Savara's score of 0.60 indicating that Cybin is being referred to more favorably in the media.

Company	Overall Sentiment
Cybin	Very Positive
Savara	Positive

Savara is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

Cybin has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market. Comparatively, Savara has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

Summary

Cybin beats Savara on 9 of the 14 factors compared between the two stocks.

How does Cybin compare to CureVac?

Cybin (NASDAQ:HELP) and CureVac (NASDAQ:CVAC) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

Cybin currently has a consensus target price of $58.75, indicating a potential upside of 1,158.03%. CureVac has a consensus target price of $6.83, indicating a potential upside of 46.64%. Given Cybin's stronger consensus rating and higher probable upside, research analysts clearly believe Cybin is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Cybin had 1 more articles in the media than CureVac. MarketBeat recorded 1 mentions for Cybin and 0 mentions for CureVac. Cybin's average media sentiment score of 1.71 beat CureVac's score of 0.00 indicating that Cybin is being referred to more favorably in the media.

Company	Overall Sentiment
Cybin	Very Positive
CureVac	Neutral

CureVac has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

CureVac has a net margin of 199.92% compared to Cybin's net margin of 0.00%. CureVac's return on equity of -23.03% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-59.98%	-50.80%
CureVac	199.92%	-23.03%	-19.09%

Cybin has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

17.9% of Cybin shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

CureVac beats Cybin on 8 of the 15 factors compared between the two stocks.

How does Cybin compare to Cronos Group?

Cronos Group (NASDAQ:CRON) and Cybin (NASDAQ:HELP) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 7.8% of Cronos Group shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cronos Group has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$146.59M	6.75	-$9.45M	$0.01	263.00
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A

In the previous week, Cronos Group had 14 more articles in the media than Cybin. MarketBeat recorded 15 mentions for Cronos Group and 1 mentions for Cybin. Cybin's average media sentiment score of 1.71 beat Cronos Group's score of 0.85 indicating that Cybin is being referred to more favorably in the news media.

Company	Overall Sentiment
Cronos Group	Positive
Cybin	Very Positive

Cybin has a net margin of 0.00% compared to Cronos Group's net margin of -1.14%. Cronos Group's return on equity of -1.26% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	-1.14%	-1.26%	-1.20%
Cybin	N/A	-59.98%	-50.80%

Cronos Group currently has a consensus target price of $2.30, indicating a potential downside of 12.55%. Cybin has a consensus target price of $58.75, indicating a potential upside of 1,158.03%. Given Cybin's stronger consensus rating and higher probable upside, analysts clearly believe Cybin is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cronos Group has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Cybin has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Summary

Cronos Group beats Cybin on 8 of the 15 factors compared between the two stocks.

How does Cybin compare to Aktis Oncology?

Cybin (NASDAQ:HELP) and Aktis Oncology (NASDAQ:AKTS) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Cybin presently has a consensus target price of $58.75, indicating a potential upside of 1,158.03%. Aktis Oncology has a consensus target price of $32.00, indicating a potential upside of 63.68%. Given Cybin's stronger consensus rating and higher probable upside, analysts clearly believe Cybin is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Aktis Oncology has higher revenue and earnings than Cybin.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A
Aktis Oncology	$6.50M	160.70	N/A	N/A	N/A

In the previous week, Aktis Oncology had 6 more articles in the media than Cybin. MarketBeat recorded 7 mentions for Aktis Oncology and 1 mentions for Cybin. Cybin's average media sentiment score of 1.71 beat Aktis Oncology's score of -0.16 indicating that Cybin is being referred to more favorably in the media.

Company	Overall Sentiment
Cybin	Very Positive
Aktis Oncology	Neutral

17.9% of Cybin shares are held by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 3.3% of Aktis Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aktis Oncology's return on equity of 0.00% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-59.98%	-50.80%
Aktis Oncology	N/A	N/A	N/A

Summary

Aktis Oncology beats Cybin on 6 of the 10 factors compared between the two stocks.

How does Cybin compare to Design Therapeutics?

Cybin (NASDAQ:HELP) and Design Therapeutics (NASDAQ:DSGN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Cybin presently has a consensus target price of $58.75, indicating a potential upside of 1,158.03%. Design Therapeutics has a consensus target price of $16.50, indicating a potential upside of 14.82%. Given Cybin's stronger consensus rating and higher probable upside, equities research analysts plainly believe Cybin is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Design Therapeutics is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

In the previous week, Design Therapeutics had 3 more articles in the media than Cybin. MarketBeat recorded 4 mentions for Design Therapeutics and 1 mentions for Cybin. Cybin's average media sentiment score of 1.71 beat Design Therapeutics' score of 0.67 indicating that Cybin is being referred to more favorably in the media.

Company	Overall Sentiment
Cybin	Very Positive
Design Therapeutics	Positive

Cybin has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market.

17.9% of Cybin shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 23.5% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Design Therapeutics' return on equity of -33.07% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-59.98%	-50.80%
Design Therapeutics	N/A	-33.07%	-31.29%

Summary

Design Therapeutics beats Cybin on 10 of the 14 factors compared between the two stocks.

Get Cybin News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HELP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HELP vs. The Competition

Export

Metric	Cybin	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$241.11M	$2.92B	$4.18B	$12.27B
Dividend Yield	N/A	15.20%	6.42%	5.35%
P/E Ratio	-1.10	13.12	22.71	25.23
Price / Sales	N/A	1,863.48	157.17	73.12
Price / Cash	N/A	26.88	53.46	56.33
Price / Book	0.59	4.18	38.77	6.90
Net Income	-$81.31M	-$42.51M	$113.55M	$333.88M
7 Day Performance	-12.05%	-0.66%	2.60%	0.01%
1 Month Performance	-15.09%	1.74%	4.57%	1.75%
1 Year Performance	N/A	16.86%	16.53%	32.67%

Cybin Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HELP Cybin	3.7994 of 5 stars	$4.67 -7.7%	$58.75 +1,158.0%	N/A	$261.26M	N/A	N/A	50
SVRA Savara	2.6805 of 5 stars	$5.08 -0.8%	$9.13 +79.6%	+76.3%	$1.05B	N/A	N/A	20	Earnings Report Analyst Revision Gap Down
CVAC CureVac	N/A	$4.66 flat	$6.83 +46.6%	N/A	$1.05B	$70.74M	6.47	880
CRON Cronos Group	1.6542 of 5 stars	$2.77 +0.7%	$2.30 -17.0%	+33.0%	$1.03B	$146.59M	277.28	450	Positive News Earnings Report Analyst Forecast
AKTS Aktis Oncology	1.666 of 5 stars	$19.73 +8.0%	$32.00 +62.2%	N/A	$975.68M	$6.50M	N/A	76	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HELP) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cybin (HELP) Competitors